AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
BAK

Braskem SA ADR (BAK) fair value

Basic Materials · Chemicals · NYSE · United States
$1.70+6.25%
Market cap $384MNext earnings 2026-11-10Updated Oct 17, 2026
Add earnings to calendarGoogle
Our verdict
Trades 11% below our fair value
Price
$1.70
Model fair valueConfidence: low
about $1.90
Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Analyst consensus.
ACCE opinionBraskem SA ADR (BAK)
Fair value
Not available
ACCE price target
$1.53
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $1.70 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
49
out of 100
Analysts
0% buy
6 covering
1-year return
-35.4%
Dividend yield
0.00%

Braskem SA ADR in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Braskem makes polypropylene, polyethylene and other base petrochemicals, plus green ethylene from Brazilian sugarcane ethanol, and sells them largely into packaging and consumer goods supply chains. The structural case rests on its position as one of the largest resin producers in the Americas, with feedstock access in Brazil and a cost curve that improves when naphtha and ethane spreads move in its favour. The near-term catalyst is the margin recovery that follows restructuring at the company and its parent Novonor, which is what drives the 21.6% revenue growth and the 17.3% operating margin on a business that still reports a deeply negative return on equity of -548.8%. At a forward P/E of 9.8 the market is pricing in a sharp earnings recovery rather than the trailing losses, so the question for the desk is whether leverage and the refinancing path leave equity holders enough of that upside. Worth a deeper look on the balance sheet and the spread outlook before any position is considered.

AI-assisted·How I use AIWritten Oct 18, 2026

Next results

Nov 10, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where BAK's valuation models land
Price
$1.70
Model fair valueConfidence: low
about $1.90
Model
Fair value
Upside
Analyst consensus
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bearish0% buy · 6 covering analysts
● Strong buy 0● Buy 0● Hold 3● Sell 1● Strong sell 2
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+2.4%
1 month
+10.4%
3 months
-30.9%
6 months
-50.0%
YTD
-42.4%
1 year
-35.4%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
15 Oct 2026, 00:00 CESTACCE price target$1.53first publication$1.87

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full BAK page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth88Value64Quality26Momentum17Total49
Valuation
Trailing P/E
no data
Forward P/E
-1.6x
PEG
no data
P/B
181.02x
EV / Revenue
0.9x
Book value/sh
BRL -6.28
Enterprise value
$12.8B
Profitability
ROE
-548.8%
FCF yield
-216.89%
ROIC
no data
Health and risk
Debt / equity
-4.42
Dividend yield
0.00%
Beta
0.67

Price

-36.1% · 1Y

Ask anything about BAK

Answered from Braskem SA ADR fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
ROEbetter than 0% of peers
low -549%-549%high 7%
Div yieldbetter than 50% of peers
low 0.0%0.0%high 5.8%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
BAK Braskem SA ADR$1.70----548.8%2649
VHI Valhi Inc. Common Stock$14.32----3.0%3248
ASIX AdvanSix Inc. Common Stock $15.71$3453% below--2.2%2726
RYAM Rayonier Advanced Materials Inc. Common Stock$6.70----49.7%1735
TROX Tronox Holdings plc Ordinary Shares (UK)$3.46----41.3%1742
SGL.DE SGL Carbon SE€4.89€344% above--7.1%4045
LXU LSB Industries Inc. Common Stock$9.89$826% above19.5x7.1%3845

Sector report card

Where BAK ranks against its sector peers on each metric.

Computing percentiles…
  • PR Newswire•Aug 18, 2026
    Braskem Idesa, S.A.P.I takes strategic action through consensual restructuring to reduce its debt by more than US$920 MM
  • Business Wire•Jul 28, 2026
    Lallemand Biofuels & Distilled Spirits and Braskem Announce Bio-Acetone as a Coproduction Opportunity in Ethanol Facilities
  • Business Wire•Jun 25, 2026
    Braskem’s Commitment to Safety Recognized with Six Texas Chemistry Council (TCC) Awards
3 more press releases · full archive on Investor+.INVESTOR
40 filings
October 2026
Oct 13
6-KForeign current reportPeriod 2026-09-30
View on SEC →
Oct 13
6-KForeign current reportPeriod 2026-09-30
View on SEC →
September 2026
Sep 28
6-KForeign current reportPeriod 2026-09-30
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR